Lipid Management in Clinical Practice (MK-0524A-115)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01071278|
Recruitment Status : Completed
First Posted : February 19, 2010
Results First Posted : March 7, 2012
Last Update Posted : August 11, 2015
|Condition or disease|
|Lipid Metabolism Disorder|
|Study Type :||Observational|
|Actual Enrollment :||2390 participants|
|Official Title:||Lipid Management in Clinical Practice|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Patients treated within a disease management program
Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
Patients treated outside a disease management program
Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
- Number of Participants With Lipid Panel Control [ Time Frame: From Visit 1 entrance evaluation (Week 0) to Visit 2 (between Weeks 8-22) ]Lipid Panel Control was defined as achieving target for one or more of the following parameters: low-density lipoprotein cholesterol (LDL-C) at goal (<100mg/dL), high-density lipoprotein cholesterol (HDL-C) within normal range (40mg/dL for males and 50mg/dL for females), and/or triglycerides within normal range (≤ 150mg/dL).
- Number of Participants Who Reported Adverse Events [ Time Frame: Up to 22 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01071278
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|